Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer

Published:2012-07 Issue:1 Volume:188 Page:103-109
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Yu Evan Y.¹,Miller Kurt²,Nelson Joel³,Gleave Martin⁴,Fizazi Karim⁵,Moul Judd W.⁶,Nathan Faith E.⁷,Higano Celestia S.¹

Affiliation:

1. University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington

2. Charité Berlin, Berlin, Germany

3. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

4. University of British Columbia, Vancouver, British Columbia, Canada

5. Institut Gustave Roussy, University of Paris Sud, Villejuif, France

6. Division of Urology, Department of Surgery and Duke Prostate Center, Duke University Medical Center, Durham, North Carolina

7. AstraZeneca Pharmaceuticals L.P., Wilmington, Delaware

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference19 articles.

1. Denosumab and bone metastasis-free survival in men with castrate-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial;Smith;Lancet,2012

2. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer;Saad;J Natl Cancer Inst,2004

3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study;Fizazi;Lancet,2011

4. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine;Cheever;Clin Cancer Res,2011

5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelin and the tumor microenvironment: a finger in every pie;Clinical Science;2024-05-24

2. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?;Progrès en Urologie;2022-06

3. Factores clínicos determinantes para la realización de pruebas de imagen en cáncer de próstata resistente a la castración no metastásico en la práctica clínica: resultados del estudio IDENTIFICA;Actas Urológicas Españolas;2021-04

4. Clinical drivers for imaging testing in non-metastatic castration-resistant prostate cancer in clinical practice: Results of the IDENTIFICA study;Actas Urológicas Españolas (English Edition);2021-04

5. Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer;Advances in Experimental Medicine and Biology;2021